Literature DB >> 16095713

Therapeutic role of mitoxantrone in multiple sclerosis.

Oliver Neuhaus1, Bernd C Kieseier, Hans-Peter Hartung.   

Abstract

Mitoxantrone is approved by several health authorities for treatment of active forms of relapsing-remitting or secondary progressive multiple sclerosis (SPMS). This review provides an outline on relevant preclinical as well as clinical studies, places mitoxantrone in the context of other therapeutic approaches against multiple sclerosis (MS), and discusses relevant side effects. The current knowledge of the putative mechanisms of action of the compound is discussed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16095713     DOI： 10.1016/j.pharmthera.2005.07.002

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  13 in total

1.  Chemotherapeutics in the treatment of multiple sclerosis.

Authors:  Bernd C Kieseier; Douglas R Jeffery
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

Review 2.  Immunosuppressive agents in multiple sclerosis.

Authors:  Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

3.  Synthesis and Solid State Structure of Fluorous Probe Molecules for Fluorous Separation Applications.

Authors:  H-J Lehmler; S Telu; S M Vyas; N S Shaikh; S E Rankin; B L Knutson; S Parkin
Journal:  Tetrahedron       Date:  2010-04-03       Impact factor: 2.457

4.  [Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval].

Authors:  J Haas; R A Linker; H P Hartung; M Meergans; S Ortler; F Tracik
Journal:  Nervenarzt       Date:  2012-12       Impact factor: 1.214

Review 5.  Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Authors:  P S Rommer; U K Zettl; B Kieseier; H-P Hartung; T Menge; E Frohman; B M Greenberg; B Hemmer; O Stüve
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 6.  Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Authors:  Til Menge; Martin S Weber; Bernhard Hemmer; Bernd C Kieseier; Hans-Christian von Büdingen; Clemens Warnke; Scott S Zamvil; Aaron Boster; Omar Khan; Hans-Peter Hartung; Olaf Stüve
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.

Authors:  Aryan Rafiee Zadeh; Mozhde Askari; Niloufar Nasr Azadani; Akram Ataei; Keyvan Ghadimi; Nooshin Tavoosi; Masih Falahatian
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-08-15

8.  Disease modifying agents for multiple sclerosis.

Authors:  Olga Hilas; Priti N Patel; Sum Lam
Journal:  Open Neurol J       Date:  2010-05-26

9.  Vitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell lines.

Authors:  Eliana Guerriero; Angela Sorice; Francesca Capone; Virginia Napolitano; Giovanni Colonna; Gabriella Storti; Giuseppe Castello; Susan Costantini
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

Review 10.  Animal models of multiple sclerosis--potentials and limitations.

Authors:  Eilhard Mix; Hans Meyer-Rienecker; Hans-Peter Hartung; Uwe K Zettl
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.